🔎 Trials Near Me

Akèy › Melanom › Texas › San Antonio

Etid klinik pou Melanom nan San Antonio, TX

15 etid pou Melanom ap chèche patisipan nan sit nan ak bò kote San Antonio (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Audie L Murphy VA Hospital, San Antonio
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Ap rekriteFaz 1/2
  • START South Texas Accelerated Research Therapeutics, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Ap rekriteEtid obsèvasyon
  • The University of Texas Health Science Center at San Antonio, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

Project: Every Child for Younger Patients With Cancer

Ap rekriteEtid obsèvasyon
  • Children's Hospital of San Antonio, San Antonio
  • Methodist Children's Hospital of South Texas, San Antonio
  • University of Texas Health Science Center at San Antonio, San Antonio
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1/2
  • Research Site, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • UT Health Mays Cancer Center, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Ap rekriteFaz 1
  • START San Antonio, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06880549

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Clinical Trial Site, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586

IDOV-Immune for Advanced Solid Tumors

Ap rekriteFaz 1
  • South Texas Accelerated Research Therapeutics, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06910657

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Ap rekriteFaz 1/2
  • Next Oncology, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT05379985

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Ap rekriteFaz 1/2
  • Next Oncology, San Antonio
  • The Start Center for Cancer Care, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Apr 28, 2026 · NCT06413680

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Ap rekriteFaz 1/2
  • Research Site, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06956690

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Ap rekriteFaz 1/2
  • NEXT Oncology, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Jan 7, 2025 · NCT06090266

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Ap rekrite
  • University of Texas Health Science Center at San Antonio, San Antonio
Laj 18 ak plis · Tout sèks · Mizajou Nov 27, 2024 · NCT03860883

Etid Melanom nan lòt vil

Lòt etid nan San Antonio

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.